ShangPharma pumps $60m into Qidong biologics plant for international clients

By Dan Stanton

- Last updated on GMT

Qidong is in the Jiangsu province
Qidong is in the Jiangsu province

Related tags Biotechnology Contract research organization Pre-clinical development

China’s ShangPharma is building a $60m (€53m) single-use biologics manufacturing plant in Qidong, to be operated by its CMO subsidiary.

China Gateway Biologics, the contract manufacturing wing of Shanghai-based pharma firm ShangPharma, will operate the facility located in the Qidong Biopharma Industrial Zone.

“The [$60m] investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale,” ​ShamgPharma’s CEO Michael Hui said in a statement today.

“We strongly believe the state-of-the-art single use facility conforming to Western standards will be able to support our international client base.”

The plant will be equipped with a 500L single-use mammalian cell culture train for clinical phase supply and two 2000L trains for commercial manufacturing, with fill & finish capabilities also available on site.

The facility is the first built in the dedicated Qidong Biopharma Industrial Zone and the investment was described by Qidong's Party Secretary Xu Feng as “a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai.”

The site will also have preclinical research capabilities which will be operated by ChemPartner – ShangPharma’s contract research organisation (CRO) business.

BeiGene in Suzhou

The news comes weeks after Beijing-based biopharma firm BeiGene announced it was building a 9,000m2 cGMP commercial biomanufacturing facility in the Suzhou Industrial Park (SIP) in Suzhou, China – about an hour West of Shanghai.

“This will be a truly cutting-edge, state of the art facility utilizing the leading technologies in biomanufacturing that will also meet the utmost regulatory standards,” ​the firm’s Head of Regulatory Affairs Wendy Yan said in August.

“Upon completion we will seek the necessary approvals to ensure our new site is fully compliant with regulatory procedures in all key global markets, including the United States, Europe and China.”

Related news

Related products

show more

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Thermo Fisher Scientific - Process Liquid Preparation Services | 21-Feb-2023 | Technical / White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Related suppliers

Follow us

Products

View more

Webinars